Aradigm Corporation, incorporated on January 30, 1991, is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. It is focused on commercializing its products in the United States, European Union (EU), Japan and China. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. The Company offers AERx pulmonary drug delivery platform and other technologies. The Company's partnered programs under development include Inhaled Ciprofloxacin. The Company is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). The Company is focused on inhaled nicotine product utilizing its AERx delivery system that is focused on addressing the acute craving for cigarettes and, through gradual reduction of the peak nicotine levels, could wean-off patients from cigarette smoking and from the nicotine addiction. ...
+See More2019-06-21 13:33:00 Friday ET
Amazon and Google face more intense antitrust scrutiny. In recent times, Justice Department and Federal Trade Commission have reached an internal agreement
2019-06-25 10:34:00 Tuesday ET
Investing in stocks is the best way for people to become self-made millionaires. A recent Gallup poll indicates that only 37% of young Americans below the a
2025-05-29 08:25:28 Thursday ET
Serial venture capitalist Ben Horowitz describes many hard truths, lessons, and insights from his entrepreneurial journey of running LoudCloud from a Silico
2018-10-05 10:38:00 Friday ET
A 7-year $1.3 billion hedge fund manager Chelsea Brennan shares her investment advice. Her advice encompasses several steps toward better financial literacy
2019-01-09 07:33:00 Wednesday ET
Apple revises down its global sales revenue estimate to $83 billion due to subpar smartphone sales in China. Apple CEO Tim Cook points out the fact that he
2018-09-01 07:34:00 Saturday ET
As the French economist who studies global economic inequality in his recent book *Capital in the New Century*, Thomas Piketty co-authors with John Bates Cl